MX2019007745A - Nuevos derivados de fenilo. - Google Patents
Nuevos derivados de fenilo.Info
- Publication number
- MX2019007745A MX2019007745A MX2019007745A MX2019007745A MX2019007745A MX 2019007745 A MX2019007745 A MX 2019007745A MX 2019007745 A MX2019007745 A MX 2019007745A MX 2019007745 A MX2019007745 A MX 2019007745A MX 2019007745 A MX2019007745 A MX 2019007745A
- Authority
- MX
- Mexico
- Prior art keywords
- phenyl derivatives
- methyl
- novel phenyl
- diabetes
- dinitrophenoxy
- Prior art date
Links
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 title abstract 2
- 208000002249 Diabetes Complications Diseases 0.000 abstract 2
- LRJQZGXEGNOHBH-UHFFFAOYSA-N 5-[(2,4-dinitrophenoxy)methyl]-1-methyl-2-nitroimidazole Chemical compound [N+](=O)([O-])C1=C(OCC2=CN=C(N2C)[N+](=O)[O-])C=CC(=C1)[N+](=O)[O-] LRJQZGXEGNOHBH-UHFFFAOYSA-N 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 210000003470 mitochondria Anatomy 0.000 abstract 1
- 230000001105 regulatory effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/88—Nitrogen atoms, e.g. allantoin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/91—Nitro radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Child & Adolescent Psychology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
La presente solicitud proporciona un nuevo derivado de fenilo 5-[(2,4-dinitrofenoxi)metil]-1-metil-2-nitro-1H-imidazol o una sal farmacéuticamente aceptable de este, el cual es útil para regular la actividad de la mitocondria, reducir la adiposidad, tratar enfermedades que incluyen diabetes y complicaciones relacionadas con la diabetes.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762443244P | 2017-01-06 | 2017-01-06 | |
| US201762581355P | 2017-11-03 | 2017-11-03 | |
| US201762585326P | 2017-11-13 | 2017-11-13 | |
| PCT/US2018/012491 WO2018129258A1 (en) | 2017-01-06 | 2018-01-05 | Novel phenyl derivatives |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2019007745A true MX2019007745A (es) | 2019-11-18 |
| MX388198B MX388198B (es) | 2025-03-19 |
Family
ID=61569353
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019007745A MX388198B (es) | 2017-01-06 | 2018-01-05 | Nuevos derivados de fenilo. |
Country Status (27)
| Country | Link |
|---|---|
| US (5) | US10618875B2 (es) |
| EP (2) | EP3565806B1 (es) |
| JP (3) | JP7090088B2 (es) |
| KR (1) | KR102579648B1 (es) |
| CN (2) | CN110167918B (es) |
| AU (1) | AU2018205811B2 (es) |
| CA (1) | CA3047138C (es) |
| CL (1) | CL2019001842A1 (es) |
| CO (1) | CO2019006865A2 (es) |
| CY (1) | CY1125182T1 (es) |
| DK (1) | DK3565806T3 (es) |
| ES (1) | ES2913431T3 (es) |
| GE (1) | GEP20217227B (es) |
| IL (1) | IL267868B (es) |
| LT (1) | LT3565806T (es) |
| MX (1) | MX388198B (es) |
| MY (1) | MY192778A (es) |
| NZ (1) | NZ754628A (es) |
| PE (1) | PE20191243A1 (es) |
| PH (1) | PH12019501318A1 (es) |
| PL (1) | PL3565806T3 (es) |
| PT (1) | PT3565806T (es) |
| SA (1) | SA519402076B1 (es) |
| SI (1) | SI3565806T1 (es) |
| UA (1) | UA124026C2 (es) |
| WO (1) | WO2018129258A1 (es) |
| ZA (1) | ZA201903808B (es) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10738035B2 (en) | 2015-05-13 | 2020-08-11 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
| SG11201807543YA (en) | 2016-03-07 | 2018-09-27 | Enanta Pharm Inc | Hepatitis b antiviral agents |
| SI3565806T1 (sl) * | 2017-01-06 | 2022-07-29 | Rivus Pharmaceuticals, Inc. | Novi fenilni derivati |
| CA3073986A1 (en) | 2017-08-28 | 2019-03-07 | Enanta Pharmaceuticals, Inc. | Hepatitis b antiviral agents |
| WO2019143902A2 (en) | 2018-01-22 | 2019-07-25 | Enanta Pharmaceuticals, Inc. | Substituted heterocycles as antiviral agents |
| KR20210065965A (ko) | 2018-09-21 | 2021-06-04 | 이난타 파마슈티칼스, 인코포레이티드 | 항바이러스제로서 작용화된 헤테로사이클 |
| SG11202105007TA (en) | 2018-11-21 | 2021-06-29 | Enanta Pharm Inc | Functionalized heterocycles as antiviral agents |
| US11236111B2 (en) | 2019-06-03 | 2022-02-01 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
| WO2020247561A1 (en) | 2019-06-04 | 2020-12-10 | Enanta Pharmaceuticals, Inc, | Hepatitis b antiviral agents |
| WO2020247575A1 (en) | 2019-06-04 | 2020-12-10 | Enanta Pharmaceuticals, Inc. | Hepatitis b antiviral agents |
| WO2021007488A1 (en) | 2019-07-11 | 2021-01-14 | Enanta Pharmaceuticals, Inc. | Substituted heterocycles as antiviral agents |
| WO2021055425A2 (en) | 2019-09-17 | 2021-03-25 | Enanta Pharmaceuticals, Inc. | Functionalized heterocycles as antiviral agents |
| WO2021188414A1 (en) | 2020-03-16 | 2021-09-23 | Enanta Pharmaceuticals, Inc. | Functionalized heterocyclic compounds as antiviral agents |
| MX2023013688A (es) | 2021-05-20 | 2024-02-27 | Rivus Pharmaceuticals Inc | Métodos de tratamiento de trastornos relacionados con la mitocondria. |
| US20250134865A1 (en) | 2022-02-07 | 2025-05-01 | Rivus Pharmaceuticals, Inc. | Methods of weight loss in a subject with elevated hba1c |
| AU2023216366A1 (en) | 2022-02-07 | 2024-08-15 | Rivus Pharmaceuticals, Inc. | Methods of weight loss and preserving skeletal muscle mass |
| WO2024112663A1 (en) | 2022-11-21 | 2024-05-30 | Rivus Pharmaceuticals, Inc. | Deuterium enriched phenyl derivatives for treating mitochondriarelated disorders or conditions |
| IL320718A (en) | 2022-11-21 | 2025-07-01 | Rivus Pharmaceuticals Inc | Crystalline forms of 5-[(2,4-dinitropenoxy)methyl]-1-methyl-2-nitro-1H-imidazole |
| CN121001992A (zh) * | 2023-05-30 | 2025-11-21 | 北京双鹤润创科技有限公司 | 咪唑基与二硝基苯基结合的衍生物及其用途 |
| CN121013841A (zh) * | 2023-06-07 | 2025-11-25 | 北京双鹤润创科技有限公司 | 咪唑基与二硝基苯基衍生物及其用途 |
| TW202515545A (zh) * | 2023-08-10 | 2025-04-16 | 大陸商深圳君聖泰生物技術有限公司 | ２，４－二硝苯酚之衍生物以及前藥、以及其組成物以及方法 |
| WO2025077675A2 (en) * | 2023-10-12 | 2025-04-17 | Shenzhen Hightide Biopharmaceutical Ltd. | Prodrugs and conjugates of 2, 4-dinitrophenol, and compositions and methods thereof |
| WO2025107532A1 (en) * | 2023-11-20 | 2025-05-30 | Beijing Double-Crane Runchuang Technology Co., Ltd. | Imidazolyl binds with dinitrophenyl derivatives and use thereof |
| CN118206492A (zh) * | 2024-03-26 | 2024-06-18 | 江南大学 | 一类2，4-二硝基苯氧基类化合物及其制备方法 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3828056A (en) * | 1972-09-11 | 1974-08-06 | Searle & Co | (2-(2-methyl-5-nitro-1-imidazolyl)ethyl)heteroaryloxy ethers |
| EG11928A (en) * | 1974-12-16 | 1979-03-31 | Hoechst Ag | Process for preparing of 1-alkyl-2-(phenoxy-methyl)-5-nitro-imidazoles |
| US5359078A (en) * | 1989-05-19 | 1994-10-25 | The United States Of America As Represented By The Department Of Health And Human Services | Signal transduction inhibitor compounds |
| EP1575575B1 (en) | 2002-11-08 | 2010-05-19 | High Point Pharmaceuticals, LLC | Safe chemical uncouplers for the treatment of obesity |
| DE602004022153D1 (de) | 2003-05-14 | 2009-09-03 | High Point Pharmaceuticals Llc | Verbindungen zur behandlung von obesitas |
| US7534805B2 (en) * | 2003-05-27 | 2009-05-19 | Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) | Imidazole derivatives, their preparation and their use as medicaments |
| JP2007513880A (ja) | 2003-11-25 | 2007-05-31 | ノボ ノルディスク アクティーゼルスカブ | 新規のサリチルアニリド |
| EP1689707A1 (en) | 2003-11-25 | 2006-08-16 | Novo Nordisk A/S | Novel compounds for the treatment of obesity |
| US20070010559A1 (en) | 2003-11-25 | 2007-01-11 | Novo Nordisk A/S | Indole derivatives for use as chemical uncoupler |
| CA2613312C (en) | 2005-06-29 | 2014-10-14 | Threshold Pharmaceuticals, Inc. | Phosphoramidate alkylator prodrugs |
| WO2008059023A1 (en) | 2006-11-15 | 2008-05-22 | High Point Pharmaceuticals, Llc | New haloalkylsulfone substituted compounds useful for treating obesity and diabetes |
| CA2669867A1 (en) | 2006-11-15 | 2008-05-22 | High Point Pharmaceuticals, Llc | 2- ( 2 -hydroxyphenyl) -quinazolin-4-ones useful for treating obesity and diabetes |
| WO2008059025A1 (en) | 2006-11-15 | 2008-05-22 | High Point Pharmaceuticals, Llc | Novel 2-(2-hydroxyphenyl) benzothiadiazines useful for treating obesity and diabetes |
| ATE523497T1 (de) | 2006-11-15 | 2011-09-15 | High Point Pharmaceuticals Llc | Neue 2-(2-hydroxyphenyl)benzimidazole, die sich für die behandlung von obesitas und diabetes eignen |
| US8946275B2 (en) | 2008-10-21 | 2015-02-03 | Threshold Pharmaceuticals, Inc. | Treatment of cancer using hypoxia activated prodrugs |
| EP2179984A1 (en) | 2008-10-27 | 2010-04-28 | Congenia S.r.l. | Acrylamido derivatives useful as inhibitors of the mitochondrial permeability transition |
| CN101560189B (zh) * | 2009-05-20 | 2011-02-16 | 南京大学 | 甲硝唑和取代水杨酸的复合物及其制法与用途 |
| WO2011162633A1 (ru) | 2010-06-24 | 2011-12-29 | Общество С Ограниченной Ответственностью "Mиtotex" | Мягкие катионные митохондриальные разобщители |
| ES2784223T3 (es) | 2012-06-20 | 2020-09-23 | Univ Virginia Patent Foundation | Composiciones y procedimientos para regular la homeostasis de glucosa y la acción de insulina |
| WO2015031598A2 (en) | 2013-08-30 | 2015-03-05 | Yale University | Therapeutic dnp derivatives and methods using same |
| US10786466B2 (en) | 2013-08-30 | 2020-09-29 | Yale University | 2,4-dinitrophenol formulations and methods using same |
| PT3164125T (pt) | 2014-07-03 | 2023-12-12 | Silti Ag | Métodos e composições para tratar obesidade, prevenir ganho de peso, promover perda de peso, promover emagrecimento ou tratar ou prevenir o desenvolvimento de diabetes |
| US20160008298A1 (en) * | 2014-07-14 | 2016-01-14 | Oregon State University | Xanthohumol-based compounds and compositions thereof, and methods of making and using the same |
| WO2016118741A1 (en) | 2015-01-22 | 2016-07-28 | Mitochon Pharmaceuticals Llc | Induced expression of brain derived neurotrophic factor (bdnf) for treatment of neuromuscular, neurodegenerative, autoimmune, developmental and/or metabolic diseases |
| MX2018010718A (es) | 2016-03-07 | 2019-06-20 | Mitochon Pharmaceuticals Inc | Tratamiento de dinitrofenol (dnp) y profarmaco de dinitrofenol (dnp) para enfermedades neuromusculares, neurodegenerativas, autoinmunes, del desarrollo, conmocion, enfermedad del ojo seco y/o metabolicas. |
| SI3565806T1 (sl) * | 2017-01-06 | 2022-07-29 | Rivus Pharmaceuticals, Inc. | Novi fenilni derivati |
| JP2020520949A (ja) | 2017-05-22 | 2020-07-16 | ユニバーシティ オブ ヴァージニア パテント ファウンデーションＵｎｉｖｅｒｓｉｔｙ Ｏｆ Ｖｅｒｇｉｎｉａ Ｐａｔｅｎｔ Ｆｏｕｎｄａｔｉｏｎ | 組成物、並びにミトコンドリア脱共役剤を調製及び使用する方法 |
-
2018
- 2018-01-05 SI SI201830676T patent/SI3565806T1/sl unknown
- 2018-01-05 EP EP18709129.3A patent/EP3565806B1/en active Active
- 2018-01-05 MX MX2019007745A patent/MX388198B/es unknown
- 2018-01-05 US US16/475,390 patent/US10618875B2/en active Active
- 2018-01-05 NZ NZ754628A patent/NZ754628A/en unknown
- 2018-01-05 JP JP2019537086A patent/JP7090088B2/ja active Active
- 2018-01-05 PE PE2019001339A patent/PE20191243A1/es unknown
- 2018-01-05 PT PT187091293T patent/PT3565806T/pt unknown
- 2018-01-05 CN CN201880005988.7A patent/CN110167918B/zh active Active
- 2018-01-05 ES ES18709129T patent/ES2913431T3/es active Active
- 2018-01-05 KR KR1020197018983A patent/KR102579648B1/ko active Active
- 2018-01-05 EP EP22157494.0A patent/EP4086242A1/en active Pending
- 2018-01-05 CN CN202310980210.0A patent/CN117024351A/zh active Pending
- 2018-01-05 LT LTEPPCT/US2018/012491T patent/LT3565806T/lt unknown
- 2018-01-05 GE GEAP201815132A patent/GEP20217227B/en unknown
- 2018-01-05 MY MYPI2019003195A patent/MY192778A/en unknown
- 2018-01-05 CA CA3047138A patent/CA3047138C/en active Active
- 2018-01-05 AU AU2018205811A patent/AU2018205811B2/en active Active
- 2018-01-05 DK DK18709129.3T patent/DK3565806T3/da active
- 2018-01-05 WO PCT/US2018/012491 patent/WO2018129258A1/en not_active Ceased
- 2018-01-05 PL PL18709129T patent/PL3565806T3/pl unknown
- 2018-01-05 UA UAA201906673A patent/UA124026C2/uk unknown
-
2019
- 2019-06-11 PH PH12019501318A patent/PH12019501318A1/en unknown
- 2019-06-12 ZA ZA2019/03808A patent/ZA201903808B/en unknown
- 2019-06-27 CO CONC2019/0006865A patent/CO2019006865A2/es unknown
- 2019-07-03 CL CL2019001842A patent/CL2019001842A1/es unknown
- 2019-07-04 IL IL267868A patent/IL267868B/en unknown
- 2019-07-07 SA SA519402076A patent/SA519402076B1/ar unknown
-
2020
- 2020-09-02 US US17/010,547 patent/US20200399225A1/en not_active Abandoned
-
2021
- 2021-04-15 US US17/231,168 patent/US20210238144A1/en not_active Abandoned
- 2021-10-28 US US17/513,235 patent/US20220048865A1/en not_active Abandoned
-
2022
- 2022-05-18 CY CY20221100338T patent/CY1125182T1/el unknown
- 2022-06-13 JP JP2022095049A patent/JP2022120118A/ja active Pending
-
2024
- 2024-06-12 JP JP2024095420A patent/JP2024116328A/ja active Pending
-
2025
- 2025-03-19 US US19/084,367 patent/US20250214944A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2019006865A2 (es) | Nuevos derivados de fenilo | |
| CL2019003126A1 (es) | Métodos de tratamiento mediante el uso de un compuesto inhibidor de jak. | |
| BR112017011316A2 (pt) | derivados heterocíclicos e uso destes | |
| BR112012004851B8 (pt) | uso de um derivado de tiazol | |
| CO2021005532A2 (es) | Derivados de quinolina como inhibidores de la integrina alfa4beta7 | |
| BR112015024530A2 (pt) | composto, métodos para tratamentos de distúrbios e de doenças e para profilaxia de distúrbios, composição farmacêutica, e, uso de um composto | |
| BR112015030399A2 (pt) | derivados heterocíclicos e uso dos mesmos | |
| MX2017015277A (es) | Derivado de pirido[3,4-d]pirimidina y sal farmaceuticamente aceptable de este. | |
| BR112018069515A2 (pt) | uso de masitinibe para tratamento de uma subpopulação de pacientes com esclerose lateral amiotrófica | |
| MX390747B (es) | Compuesto heterociclico sustituido con alquinilo, su metodo de preparacion y su uso medico. | |
| MX389014B (es) | Formas cristalinas de un compuesto inhibidor de jak | |
| BR112017008312A2 (pt) | novos compostos de piridopirimidinona para modular a atividade catalítica de histona lisina demetilases (kdms) | |
| ECSP22054240A (es) | Compuesto y composici?n como inhibidor de quinasa del receptor pdgf | |
| CY1119483T1 (el) | Θεραπευτικος παραγων για τις αγχωδεις διαταραχες | |
| UY33568A (es) | Compuestos que interactuan con proteina reguladora de glucocinasa para el tratamiento de diabetes. | |
| AR114418A1 (es) | Compuesto cíclico de metilactama y su utilización farmacéutica | |
| CL2012002375A1 (es) | Composicion para controlar enfermedades vegetales que comprende un derivado de amida y uno o mas comuestos fungicidas de carbamatos; metodo para controlar una enfermedad vegetal que comprende aplicar la composicion antes mencionada; uso de la composicion para controlar una enfermedad vegetal. | |
| PE20242220A1 (es) | Combinacion de regonafenib e inhibidores de pd-1/pd-l1(2) para el tratamiento contra el cancer | |
| BR112012024346A2 (pt) | agente terapêutico ou agente profilático para a doença de alzheimer | |
| EA201991180A1 (ru) | Новые фенильные производные | |
| MX384748B (es) | Compuestos derivados de carboxamida y el uso de los mismos para controlar endoparásitos en mamíferos. | |
| WO2016089062A3 (en) | Heterocyclic derivatives and use thereof | |
| MX374120B (es) | Compuestos derivados de carboxamida y el uso de los mismos para controlar endoparásitos en mamíferos. |